Multivalent Aptamer–RNA Conjugates for Simple and Efficient Delivery of Doxorubicin/siRNA into Multidrug‐Resistant Cells

Jeong, Hyosook; Lee, Soo Hyun; Hwang, Yeonju; Yoo, Hyundong; Jung, Heesun; Kim, Sun Hwa; Mok, Hyejung

doi:10.1002/mabi.201600343

Cited by 43 publications

(32 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dox fluorescent signal at dsi-motif/Dox molar ratio of 1:1 was significantly reduced below 10% both at 24°C and at 37°C. More than 90% of initial Dox was intercalated within ds-i-motif, which is consistent to previous studies [17,18,22,24]. In this study, we used a one base pair mismatched DNA sequence (flare) as a complementary sequence for the i-motif.…”

Section: Intercalation and Ph-dependent Release Of Doxsupporting

confidence: 86%

I-motif-coated exosomes as a pH-sensitive carrier for anticancer drugs

et al. 2018

Self Cite

View full text Add to dashboard Cite

Nature-derived exosomes have been noted as emerging carriers for anticancer drugs. In this study, as a proof-of-concept, the anticancer drug doxorubicin (Dox) was loaded onto i-motif-modified exosomes (Exo-i-motif) to deliver Dox to cancer cells efficiently. The doublestranded biotin-i-motif/flare (ds-i-motif-bio)s efficiently released Dox in an acidic pH-responsive manner within 1 h. Based on gel electrophoresis, it was clearly confirmed that ds-i-motif-bio successfully interacts with biotin-conjugated exosomes and streptavidin (strep) via the biotinstreptavidin interaction. The particle sizes were below 150 nm without aggregation after strep-mediated modification of ds-i-motif-bio on the surfaces of the exosomes. In addition, released Dox had intact bioactivity for anti-proliferation after immobilization onto the exosomes. This study could serve as a new concept of pH-responsive delivery systems of anticancer drug using nature-derived exosomes with i-motifs.

show abstract

Section: Intercalation and Ph-dependent Release Of Doxsupporting

confidence: 86%

I-motif-coated exosomes as a pH-sensitive carrier for anticancer drugs

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…This progression might contribute to the clinical translation of osteoblast-specific aptamer-RNAi-based treatments for bone disease. Nowadays, targeted siRNA delivery using an aptamer-siRNA chimera is being actively studied [ 87 , 88 , 89 ].…”

Section: Applications Of Aptamers In Biomedicinementioning

confidence: 99%

Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine

Zhang

Wang

et al. 2017

IJMS

340

205

View full text Add to dashboard Cite

Aptamers are short DNA/RNA oligonucleotides capable of binding to target molecules with high affinity and specificity. The process of selecting an aptamer is called Systematic Evolution of Ligands by Exponential Enrichment (SELEX). Thanks to the inherit merits, aptamers have been used in a wide range of applications, including disease diagnosis, targeted delivery agents and therapeutic uses. To date, great achievements regarding the selection, modifications and application of aptamers have been made. However, few aptamer-based products have already successfully entered into clinical and industrial use. Besides, it is still a challenge to obtain aptamers with high affinity in a more efficient way. Thus, it is important to comprehensively review the current shortage and achievement of aptamer-related technology. In this review, we first present the limitations and notable advances of aptamer selection. Then, we compare the different methods used in the kinetic characterization of aptamers. We also discuss the impetus and developments of the clinical application of aptamers.

show abstract

“…The complex was efficient in delivering doxorubicin to multi drug resistant MCF-7 cells because of increased endocytosis efficiency due to the cluster effect. BCL-2 RNAsi acted synergistically with DOX, increasing the sensitivity of cells for apoptosis and, in turn, decreasing cell viability [60].…”

Section: Tumor-targeted Aptamers Complexed Directly To Sirnas and Othmentioning

confidence: 99%

Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer

Almeida

et al. 2019

Pharmaceutics

View full text Add to dashboard Cite

Both aptamers and siRNA technologies have now reached maturity, and both have been validated with a product in the market. However, although pegaptanib reached the market some time ago, there has been a slow process for new aptamers to follow. Today, some 40 aptamers are in the market, but many in combination with siRNAs, in the form of specific delivery agents. This combination offers the potential to explore the high affinity and specificity of aptamers, the silencing power of siRNA, and, at times, the cytotoxicity of chemotherapy molecules in powerful combinations that promise to delivery new and potent therapies. In this review, we report new developments in the field, following up from our previous work, more specifically on the use of aptamers as delivery agents of siRNA in nanoparticle formulations, alone or in combination with chemotherapy, for the treatment of cancer.

show abstract

Multivalent Aptamer–RNA Conjugates for Simple and Efficient Delivery of Doxorubicin/siRNA into Multidrug‐Resistant Cells

Cited by 43 publications

References 40 publications

I-motif-coated exosomes as a pH-sensitive carrier for anticancer drugs

I-motif-coated exosomes as a pH-sensitive carrier for anticancer drugs

Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine

Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer

Contact Info

Product

Resources

About